NCT01098266 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 200
- group Id
- BG001
- value
- 200
- group Id
- BG002
- value
- 400
- units
- Participants
- groups
- description
- NGR-hTNF plus Best Investigator's Choice NGR-hTNF plus Best Investigator's Choice (BIC): - NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs. * Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis * Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination: 1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
- id
- BG000
- title
- A: NGR-hTNF + BIC
- description
- Placebo plus Best Investigator's Choice Placebo plus Best Investigator's Choice (BIC): - Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs. * Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis * Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination: 1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
- id
- BG001
- title
- B: Placebo+BIC
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 87
- group Id
- BG002
- value
- 179
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 108
- group Id
- BG001
- value
- 113
- group Id
- BG002
- value
- 221
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 25
- upper Limit
- 89
- value
- 65
- group Id
- BG001
- lower Limit
- 31
- upper Limit
- 81
- value
- 67
- group Id
- BG002
- lower Limit
- 25
- upper Limit
- 89
- value
- 66
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 44
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 99
- title
- Female
- measurements
- group Id
- BG000
- value
- 156
- group Id
- BG001
- value
- 145
- group Id
- BG002
- value
- 301
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 198
- group Id
- BG001
- value
- 197
- group Id
- BG002
- value
- 395
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 8
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Sweden
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 13
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 26
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Ireland
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 36
- title
- Egypt
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 31
- title
- Poland
- categories
- measurements
- group Id
- BG000
- value
- 79
- group Id
- BG001
- value
- 84
- group Id
- BG002
- value
- 163
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 49
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 95
- title
- United Kingdom
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 10
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- Spain
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- Patients ≥ 18 years with advanced malignant pleural mesothelioma previously treated with a pemetrexed based chemotherapy regimen for advanced or metastatic disease.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 200
- group Id
- BG001
- value
- 200
- group Id
- BG002
- value
- 400
- units
- Participants
- groups
- description
- NGR-hTNF plus Best Investigator's Choice NGR-hTNF plus Best Investigator's Choice (BIC): - NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs. * Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis * Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination: 1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
- id
- BG000
- title
- A: NGR-hTNF + BIC
- description
- Placebo plus Best Investigator's Choice Placebo plus Best Investigator's Choice (BIC): - Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs. * Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis * Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination: 1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
- id
- BG001
- title
- B: Placebo+BIC
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 87
- group Id
- BG002
- value
- 179
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 108
- group Id
- BG001
- value
- 113
- group Id
- BG002
- value
- 221
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 25
- upper Limit
- 89
- value
- 65
- group Id
- BG001
- lower Limit
- 31
- upper Limit
- 81
- value
- 67
- group Id
- BG002
- lower Limit
- 25
- upper Limit
- 89
- value
- 66
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 44
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 99
- title
- Female
- measurements
- group Id
- BG000
- value
- 156
- group Id
- BG001
- value
- 145
- group Id
- BG002
- value
- 301
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 198
- group Id
- BG001
- value
- 197
- group Id
- BG002
- value
- 395
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 8
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Sweden
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 13
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 26
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Ireland
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 36
- title
- Egypt
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 31
- title
- Poland
- categories
- measurements
- group Id
- BG000
- value
- 79
- group Id
- BG001
- value
- 84
- group Id
- BG002
- value
- 163
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 49
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 95
- title
- United Kingdom
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 10
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- Spain
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- Patients ≥ 18 years with advanced malignant pleural mesothelioma previously treated with a pemetrexed based chemotherapy regimen for advanced or metastatic disease.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle